Patrick Phuong
About Patrick Phuong
Patrick Phuong serves as the Senior Director of Clinical Science at Arcus Biosciences, where he leads the Lung Disease Area Team. He has extensive experience in clinical science, having previously held positions at several notable companies, including Pfizer, Genentech, and Atara Biotherapeutics.
Work at Arcus Biosciences
Patrick Phuong currently serves as Senior Director of Clinical Science at Arcus Biosciences, a position he has held since 2023. He previously worked as Director of Clinical Science from 2021 to 2023 and as Associate Director of Clinical Science from 2020 to 2021. In these roles, he has led the Lung Disease Area Team and focused on immuno-oncology, contributing to the development of therapies across various tumor types.
Education and Expertise
Patrick Phuong earned a Bachelor of Science (B.S.) in Biochemistry from the University of California, San Diego (UCSD) from 2007 to 2011. He furthered his education by obtaining a Doctor of Pharmacy (Pharm.D.) from UCSD's Skaggs School of Pharmacy and Pharmaceutical Sciences from 2011 to 2015. Additionally, he completed a Post-Doctoral Fellowship in Clinical Science - Translational Medicine at Rutgers University-New Brunswick from 2015 to 2017.
Background
Patrick Phuong has extensive experience in clinical science and pharmacology. He began his career as a Clinical Research Intern at UC San Diego from 2012 to 2015. He has held various positions in notable organizations, including Pfizer, Genentech, and Atara Biotherapeutics, where he focused on clinical science and pharmacology. His work experience spans roles as a Clinical Sciences Fellow and Associate Director of Clinical Science.
Achievements
Throughout his career, Patrick Phuong has gained significant experience in small molecule, monoclonal antibody, and cell-based therapies. His strong focus on immuno-oncology has positioned him as a leader in the field, particularly in developing treatments for a broad range of tumor types. His leadership at Arcus Biosciences highlights his commitment to advancing clinical science in oncology.